Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity
- Sponsor
- Reade Rheumatology Research Institute
- Study ID
- NCT04222920
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dose reduction to 2mg/L — OTHERAdalimumab dose reduction aiming drug concentration of 2mg/L
- Dose reduction to 5mg/L — OTHERAdalimumab dose reduction aiming drug concentration of 5mg/L
- Adalimumab — DRUGAdalimumab
Study Details
Several prior studies have shown that dose reduction or discontinuation of tumor necrosis factor (TNF)-inhibitors, like adalimumab, is possible in substantial number of patients with a rheumatic disease without an increase in disease activity. Prior studies showed that patients with concentrations higher than 5 mg/L are overexposed to adalimumab and can safely reduce the dose. In the first phase of treatment, an adalimumab concentration of 5mg/L is needed to achieve adequate clinical response. However to control disease activity after 28 weeks, lower concentration than 5 mg/L are probably sufficient. Recent published data suggest that concentrations of 0.1-0.5 mg/L are enough to control TNF blockade in this state. Yet, a study which investigates the lowest effective drug serum concentration is missing so far. The hypothesis is that serum adalimumab concentration of 2 mg/L is sufficient to control disease activity.
Key Dates
- Start date
- Mar 1, 2020
- Status verified
- Nov 2023
- Primary completion
- Sep 11, 2023
- Completion
- Sep 11, 2023
Study Design
- Enrollment
- 78 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Low serum drug concentrationAdalimumab dose reduction aiming a drug level of 2 mg/L
- Active Comparator: High serum drug concentrationAdalimumab dose reduction aiming a drug level of 5 mg/L
Primary Outcome Measure
Mean time weighted DAS28-CRP [ Time Frame: after 24 weeks ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina